Compare Linde PLC (LIN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Regeneron Pharmaceuticals Inc — how do they compare? Linde PLC trades at $505 (market cap $236.74B), while Regeneron Pharmaceuticals Inc trades at $671.32 (market cap $70.47B). The key difference: Linde PLC is far larger — about 3.4× Regeneron Pharmaceuticals Inc's market cap, and Linde PLC pays the higher dividend (1.25%). Which is the better fit depends on your goals.
| LIN | REGN | |
|---|---|---|
Market Cap | $236.74B | $70.47B |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $812.27 |
52-Week Low | $389.38 | $545.46 |
Enterprise Value | $259.10B | $64.42B |
Dividend Yield | 1.25% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $513.07, down 1.47% today, with strong fundamentals including 20.44% net income margin and consistent earnings beats. Technical indicators show a bearish trend with support at $509 and resistance at $520. The company maintains robust cash flow from operations of $10.35B and has raised dividends, reflecting financial health.
Outlook remains positive with 89% analyst buy ratings and a $564.80 price target, though valuation ratios are elevated. Risks include rising debt-to-asset ratio (31.63% in 2025) and potential macroeconomic pressures. The stock offers growth potential but requires monitoring of leverage and market conditions.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
